Clinical Trial Update: Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of buparlisib (BKM120) in patients with metastatic non-small cell lung cancer; results posted in February 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BKM120 (Buparlisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-02